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OBJECTIVES:To describe the key financial resources allocation supporting the HIV/
AIDS prevention, treatment, and social support programs in Thailand and to iden-
tify facilitators and barriers in financial management and monitoring system.
METHODS: Based on a comprehensive review of financial reports from various
sources such as UNGASS, NASA and NAMC reports, we explored the key financial
resources that support the HIV/AIDS prevention, treatment, and social support
programs in Thailand. In addition, we conducted in-depth interviews with differ-
ent key informants responsible for the activities in response to the national policy
on HIV/AIDS in provincial and district levels including domestic and international
donors to assess the financial management, coordination and monitoring system.
RESULTS: The total expenditure on HIV/AIDS in fiscal years 2007, 2008 and 2009
were 204, 210, and 218 million US$, respectively. The national HIV/AIDS spending
was amount to 2.7% (2007) and 1.9% (2008 and 2009) of the total health expenditure.
Domestic funding accounted for 83%, 85% and 93% of the HIV/AIDS programs in
2007, 2008 and 2009. Much of those spending emphasized on care and treatment
while prevention budgeted for 14.1%, 21.7%, and 13.7%. The majority of treatment
financing came from public health insurance schemes, but most preventive pro-
grams were from GFATM and other international sources. Effective system devel-
opment in program management, monitoring and evaluation are still lacking
among practitioners. CONCLUSIONS: Thailand has shown its potential to be self-
reliant in combating HIV/AIDS. Nevertheless, care and treatment expenditures
overshadow prevention, and most of the preventive programs are from interna-
tional sources. Thus, the dominance of entitlement programs in funding for HIV/
AIDS treatment challenges policy makers to monitor the extent and quality of
HIV/AIDS care. For future savings in the cost of treatment and care, investing in
prevention programs is essential, especially due to the declining support from
international funds.
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OBJECTIVES: One in four HIV infected patients is unaware of his condition, and
implies a threefold increase in the risk of HIV transmission. To describe the out-
comes, users’ socio-demographic characteristics and test acceptance of a new
rapid HIV antibody screening test programme offered at Basque community
pharmacies. METHODS: Cross-sectional study based on the answers given by the
users of the rapid HIV antibody screening test, to a questionnaire. The programme
was performed in 20 community pharmacies. Data shown come from a random
sample of the 3514 tests carried out in the first year of the programme. Data gath-
ered include test outcomes, users’ socio-demographic information, their HIV risk
profile, the reasons for asking for the test, and why they chose community phar-
macies to have the HIV test. Statistical analyses included exact tests. RESULTS:
There were 806 valid questionnaires, the mean age of test users was 36.2 years (SD:
11.0; range: 16-82; 71% men). 7 HIV test outcome were positive (0.85%; 95%CI: 0.34 to
1.75), 5 out of them were men. Only 10% of test users came from another country.
Users’ risk behaviour was predominantly heterosexual and 1 in 5 users asked for
the test in the following three months after the exposure to the risk factor, when
the test is not still accurate. More than half of the users hadn’t had a previous HIV
test. The reasons for choosing this kind of HIV test were mainly its quickness (just
15 minutes), and the convenience and rapid access to a community pharmacy
service. The cost of each test for the Basque Government in 2010 was 18.15€
(1887.57€ to detect a positive one). CONCLUSIONS: This new rapid HIV antibody
screening test in community pharmacies can supplement other HIV screening
programs running as the user profile partially differs from them.
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OBJECTIVES: Tobramycin inhaled solution (TIS) has been shown to preserve lung
function in cystic fibrosis (CF) patients chronically infected with Pseudomonas
aeruginosa. To minimize the emergence of aminoglycoside resistant P. aeruginosa
strains, a chronic intermittent treatment of 28 days on and 28 days off TIS is rec-
ommended. The objective of this study was to assess TIS utilization modalities in
CF patients. METHODS: Patients covered by the provincial public drug reimburse-
ment program who had used TIS (Tobi™) on at least one occasion during the period
from January 1, 2007 to December 31, 2008 were selected. To be included in the
study they needed to be cover by the drug program for at least one year after the
initiation of TIS. Patient’s characteristics and drug utilization patterns were ana-
lyzed. For each patient, the number of 28 days periods for which they received TIS
was estimated RESULTS: There were a total of 72 patients who have use TIS during
the study period and were covered by the drug plan for at least one year after the
initiation of TIS. The average age of TIS users was 25.6 years, with a similar pro-
portion of males (51.4%) and females (48.6%). A large proportion of these patients
(40,3%) had diabetes. In the first year following the initiation of TIS, different pat-
terns of utilization were observed: For 15.3% of these patients, TIS was use as a
continuous treatment (42 weeks or more of treatment), 41.7% received 4 cycles or
more, 22.2% received 2 or 3 cycles and 20.8% received only 1 cycle of TIS during the
year. CONCLUSIONS: In this sample, the utilization of TIS in CF patients was sub-
optimal. TIS was used as recommended, as a chronic intermittent treatment by
less than half of the study population.
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OBJECTIVES: Chronic infection with Hepatitis C virus is causing advanced liver
disease in a large proportion of patients. Standard treatment is antiviral therapy
with the goal of a sustained virological response (SVR). The objective of the study is
to validate SVR in the chronic infection Hepatitis C as patient relevant endpoint as
defined by German code of social law. METHODS: Systematic literature searches
were conducted in order to find relevant methods for the validation of surrogate
endpoints in general and to find studies with appropriate data to perform the
validation of SVR as a surrogate parameter in Hepatitis C. The validation will be
realised with the best method according to the data available from the selected
studies. RESULTS: Five studies were identified as basis for validation (out of 694
papers retrieved and 36 studies selected for further analysis). Due to the lack of
long-term studies fulfilling the defined inclusion criteria, no differentiation be-
tween antiviral treatment schemes and different stages of the disease were possi-
ble. Methods of Prentice were identified as applicable for validation. With the four
Prentice criteria, SVR could be validated as a surrogate endpoint for the endpoints
liver cancer and mortality. However, this was not possible with data from all five
studies and only partly with different analysis methods (combination) of data. For
regression models or meta-analysis, data is not sufficient since individual patient
data was not available. For one study further analysis (proportion of treatment
effect) could be performed. CONCLUSIONS:When focussing on statistical methods
current data allows for a very limited validation of SVR as a patient-relevant end-
point for treatment of Hepatitis C, only. There is a lack of long-term data (going
beyond 5 years of follow up), especially for individual data of treated and untreated
patients, likely due to the slow-evolving character of Hepatitis C.
PIN109
MODELLING THE POLICY OF MANAGING SEASONAL INFLUENZA IN THE UK
Van Bellinghen LA1, Van Vlaenderen I1, Meier GC2
1CHESS BVBA, Ternat, Belgium, 2GlaxoSmithKline Biologicals, Wavre, Belgium
OBJECTIVES: Seasonal influenza policy in the UK is directed to the elderly and
selected high-risk groups. The department of Health Policy suggests that these
individuals should be vaccinated every year to avoid possible costly or life-threat-
ening complicationsTo define a cost-effectiveness modelling approach and struc-
ture that reflects the season-to-season impact of influenza on the entire UK popu-
lation, and the consequences of policyMETHODS:A structured, iterative, literature
review and analysis of seasonal influenza models RESULTS: Fifty-four references
were reviewed, 32 were assessed. The vast majority of models are decision trees,
considering one influenza season; however, if unit of outcome was life years or
QALYs, impact of influenza mortality was incorporated as average life-expectancy
foregone. Nine models considered healthy and at-risk paediatric populations, six
were UK models of which three papers considered treatment only and the remain-
ing considered treatment and prevention. Ten models reviewed healthy working
adult populations only, two were UK models, one considering prevention, the other
treatment. Sixteen other models reviewed adult populations (healthy and/or at-
risk adults, excluding healthy working adults), nine were UK models. Eleven papers
considered treatment only, two considered prevention only and the remaining
considered treatment and prevention. Twenty-one models evaluated the elderly,
including residential populations. Nine were UK papers; five considered treatment
only and four considered treatment and prevention. CONCLUSIONS: No study as-
sessed the cost-effectiveness in the entire population, only sub-group analyses
have been performed. None of the studies considered the impact of policy options
over multiple consecutive flu seasons during a lifelong time horizon, and – as a
consequence – were not able to incorporate accumulated (Quality Adjusted) Life
Years gained for various age groups. Our suggested approach is a one-year cycle
length, life-time, multi-cohort, Markov model from the perspective of the NHS,
with cohorts starting in different age groups and accounting for at-risk popula-
tions.
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OBJECTIVES: Development of a unique database using data from studies con-
ducted during the vaccine development and its post-marketing to evaluate the
safety profile of a virosomal aluminium-free hepatitis A vaccine in a large
population. METHODS: Available data from various studies, retrieved either from
paper or electronic files, were evaluated and harmonized in order to be combined in
a single database and all adverse events, concomitant diseases and concomitant
vaccinations underwent a new coding. RESULTS: Initial data were available from 3
distinct sources, totalizing 35 studies: individual and summary data from clinical
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